Molecular Templates Stock Current Valuation
| MTEM Stock | USD 0.34 0.04 10.53% |
Valuation analysis of Molecular Templates helps investors to measure Molecular Templates' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Molecular Templates' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 25th of November 2024, Enterprise Value Multiple is likely to grow to 12.85, while Enterprise Value is likely to drop about 16.6 M. Fundamental drivers impacting Molecular Templates' valuation include:
Price Book 0.3104 | Enterprise Value 940.6 K | Enterprise Value Ebitda 0.1468 | Price Sales 0.0867 | Enterprise Value Revenue 0.0401 |
Undervalued
Today
Please note that Molecular Templates' price fluctuation is dangerous at this time. Calculation of the real value of Molecular Templates is based on 3 months time horizon. Increasing Molecular Templates' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Molecular stock is determined by what a typical buyer is willing to pay for full or partial control of Molecular Templates. Since Molecular Templates is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Molecular Stock. However, Molecular Templates' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.34 | Real 9.63 | Target 37.5 | Hype 0.34 | Naive 0.18 |
The intrinsic value of Molecular Templates' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Molecular Templates' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Molecular Templates helps investors to forecast how Molecular stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Molecular Templates more accurately as focusing exclusively on Molecular Templates' fundamentals will not take into account other important factors: Molecular Templates Company Current Valuation Analysis
Molecular Templates' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Molecular Templates Current Valuation | 940.57 K |
Most of Molecular Templates' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Templates is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Molecular Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Molecular Templates is extremely important. It helps to project a fair market value of Molecular Stock properly, considering its historical fundamentals such as Current Valuation. Since Molecular Templates' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Molecular Templates' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Molecular Templates' interrelated accounts and indicators.
Click cells to compare fundamentals
Molecular Current Valuation Historical Pattern
Today, most investors in Molecular Templates Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Molecular Templates' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Molecular Templates current valuation as a starting point in their analysis.
Molecular Templates Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Molecular Templates has a Current Valuation of 940.57 K. This is 99.99% lower than that of the Biotechnology sector and 99.98% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Molecular Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Templates' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Molecular Templates could also be used in its relative valuation, which is a method of valuing Molecular Templates by comparing valuation metrics of similar companies.Molecular Templates is currently under evaluation in current valuation category among its peers.
Molecular Templates Current Valuation Drivers
We derive many important indicators used in calculating different scores of Molecular Templates from analyzing Molecular Templates' financial statements. These drivers represent accounts that assess Molecular Templates' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Molecular Templates' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 528.4M | 447.0M | 216.8M | 18.6M | 16.8M | 16.0M | |
| Enterprise Value | 457.6M | 448.9M | 236.8M | 37.0M | 17.5M | 16.6M |
Molecular Fundamentals
| Return On Equity | -9.29 | ||||
| Return On Asset | -0.38 | ||||
| Profit Margin | (0.61) % | ||||
| Operating Margin | (14.50) % | ||||
| Current Valuation | 940.57 K | ||||
| Shares Outstanding | 6.58 M | ||||
| Shares Owned By Insiders | 3.96 % | ||||
| Shares Owned By Institutions | 35.00 % | ||||
| Number Of Shares Shorted | 270.13 K | ||||
| Price To Earning | (0.24) X | ||||
| Price To Book | 0.31 X | ||||
| Price To Sales | 0.09 X | ||||
| Revenue | 57.31 M | ||||
| Gross Profit | (45.97 M) | ||||
| EBITDA | 1.43 M | ||||
| Net Income | (8.12 M) | ||||
| Cash And Equivalents | 104.42 M | ||||
| Cash Per Share | 1.85 X | ||||
| Total Debt | 12.23 M | ||||
| Debt To Equity | 1.79 % | ||||
| Current Ratio | 2.40 X | ||||
| Book Value Per Share | 1.08 X | ||||
| Cash Flow From Operations | (41.82 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (3.05) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 62 | ||||
| Beta | 1.22 | ||||
| Market Capitalization | 2.21 M | ||||
| Total Asset | 35.38 M | ||||
| Retained Earnings | (452.89 M) | ||||
| Working Capital | (549 K) | ||||
| Current Asset | 54.36 M | ||||
| Current Liabilities | 7.75 M | ||||
| Net Asset | 35.38 M |
About Molecular Templates Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Templates's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Templates using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Templates based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Molecular Templates Piotroski F Score and Molecular Templates Altman Z Score analysis. To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Templates. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Templates listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.97) | Earnings Share (3.05) | Revenue Per Share 4.544 | Quarterly Revenue Growth (0.92) | Return On Assets (0.38) |
The market value of Molecular Templates is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Templates' value that differs from its market value or its book value, called intrinsic value, which is Molecular Templates' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Templates' market value can be influenced by many factors that don't directly affect Molecular Templates' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Templates' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Templates is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Templates' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.